Insight

Isabella Michelon: Meta-analysis of 2000+ patients with HER2-low and MBC

Isabella Michelon/LinkedIn

Nov 24, 2024, 19:37

Isabella Michelon: Meta-analysis of 2000+ patients with HER2-low and MBC

Isabella Michelon, 6th year medical student at the Catholic University of Pelotas, shared a recent article on X:

“Proud to share our work in Therapeutic Advances in Medical Oncology.

Our meta-analysis of 2000+ patients with HER2-low and MBC reveals a 50% reduction in the risk of progression and death with ADCs compared to chemotherapy.”

Title: Antibody–drug conjugates in patients with advanced/metastatic HER2-low-expressing breast cancer: a systematic review and meta-analysis

Authors: Isabella Michelon, Maria Inez Dacoregio, Maysa Vilbert, Jonathan Priantti, Caio Ernesto do Rego Castro, Lucas Vian, Paolo Tarantino, Evandro de Azambuja, and Ludimila Cavalcante

Isabella Michelon

For more updates, follow OncoDaily.

antibody antibody drug Breast Cancer Caio Ernesto do Rego Castro cancer chemotherapy drug Evandro de Azambuja HER2-low Isabella Michelon Jonathan Priantti Lucas Vian Ludimila Cavalcant Maria Inez Dacoregio Maysa Vilbert MBC meta-analysis OncoDaily Oncology Paolo Tarantino Therapeutic Advances in Medical Oncology

NEW PAPER ALERT: Efficacy of CDK4/6 Inhibitors and Endocrine Therapy in HR+/HER2- Advanced Breast Cancer by PAM50 Subtype: SOLTI-1801 CDK-PREDICT Results

Oncologist Near Me – Fabrice André: Leading Expert in Breast Cancer

Funding Impactful Cancer Research That Might Otherwise Go Unsupported: Ryan Schoenfeld on the Secret Behind Mark Foundation’s Success

One Hand Gives, Another Takes? Trump, Musk, Congress and Childhood Cancer Research Funding

Fabrice André has been elected as the President of the ESMO for the term 2025-2026

Special Coverage